Status of Serum Iron and Copper in Women Taking Oral Contraceptive

Hasanat, F; Chakroborty, PK; Hasanat, A; Sharmin, SK; Mannan, MB; Nargis, Susmita

doi:10.3329/bjmb.v10i1.36692

Cited by 1 publication

(2 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral contraceptives have the potential to increase iron stores in their users by way of reducing menstrual iron losses, therefore decreasing iron deficiency [ 12 , 13 , 14 , 15 ]. As illustrated above, there are emerging brands of oral contraceptives, which include supplemental iron in the placebo tablets.…”

Section: Resultsmentioning

confidence: 99%

“…Oral contraceptives are known to reduce the duration and amount of menstrual blood loss throughout the menstrual cycle, potentially resulting in lower menstrual iron losses [ 11 ]. Interestingly, oral contraceptive users have been shown to have higher serum iron levels compared to non-oral contraceptive users [ 12 , 13 , 14 , 15 ]. In a population survey of 676 premenopausal Danish women (>35 years of age), serum ferritin concentrations were found to be inversely associated with the duration of menses ( p < 0.0001) [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Iron-Containing Oral Contraceptives and Their Effect on Hemoglobin and Biomarkers of Iron Status: A Narrative Review

2021

View full text Add to dashboard Cite

Oral contraceptive use has been associated with decreased menstrual blood losses; thus, can independently reduce the risk of anemia and iron deficiency in women. Manufacturers have recently started to include supplemental iron in the non-hormonal placebo tablets of some contraceptives. The aims of this narrative review are: (i) to describe the relationship between oral contraceptive use and both anemia and iron status in women; (ii) to describe the current formulations of iron-containing oral contraceptives (ICOC) available on the market; and (iii) to systematically review the existing literature on the effect of ICOC on biomarkers of anemia and iron status in women. We discovered 21 brands of ICOC, most commonly including 25 mg elemental iron as ferrous fumarate, for seven days, per monthly tablet package. Our search identified one randomized trial evaluating the effectiveness of ICOC use compared to two non-ICOC on increasing hemoglobin (Hb) and iron status biomarker concentrations in women; whereafter 12 months of contraception use, there were no significant differences in Hb concentration nor markers of iron status between the groups. ICOC has the potential to be a cost-effective solution to address both family planning needs and iron deficiency anemia. Yet, more rigorous trials evaluating the effectiveness of ICOC on improving markers of anemia and iron deficiency, as well as investigating the safety of its consumption among iron-replete populations, are warranted.

show abstract